Vincerx Pharma, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Vincerx Pharma, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($30.07M) | Mar 27, 2025 |
| FY2024 | Dec 31, 2023 | ($40.16M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($62.98M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($39.31M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | ($16.62M) | Mar 29, 2022 |
| FY2020 | Jun 30, 2020 | ($119.5K) | Sep 23, 2020 |
| FY2020 | Dec 31, 2019 | ($45.0K) | May 14, 2021 |
| FY2020 | Jun 30, 2019 | ($1.5K) | Sep 23, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($31.46M) | Mar 27, 2025 |
| FY2024 | Dec 31, 2023 | ($42.61M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($71.19M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($62.66M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | ($10.71M) | Mar 29, 2022 |
| FY2020 | Jun 30, 2020 | ($173.0K) | Sep 23, 2020 |
| FY2020 | Dec 31, 2019 | ($45.0K) | May 14, 2021 |
| FY2020 | Jun 30, 2019 | ($1.5K) | Sep 23, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($26.13M) | Mar 27, 2025 |
| FY2024 | Dec 31, 2023 | ($40.45M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($59.60M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($33.40M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | ($2.28M) | Mar 29, 2022 |
| FY2020 | Jun 30, 2020 | ($165.3K) | Sep 23, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $8.01M | Mar 27, 2025 |
| FY2024 | Dec 31, 2023 | $18.22M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $59.29M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $117.68M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $63.19M | Mar 29, 2022 |
| FY2020 | Jun 30, 2020 | $66.48M | Sep 23, 2020 |
| FY2020 | Jun 30, 2019 | $25.0K | Sep 23, 2020 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $5.28M | Mar 27, 2025 |
| FY2024 | Dec 31, 2023 | $7.00M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $11.62M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $17.36M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $37.81M | Mar 29, 2022 |
| FY2020 | Jun 30, 2020 | $3.41M | Sep 23, 2020 |
| FY2020 | Dec 31, 2019 | $44.0K | May 14, 2021 |
| FY2020 | Jun 30, 2019 | $1.5K | Sep 23, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $2.72M | Mar 27, 2025 |
| FY2024 | Dec 31, 2023 | $11.22M | Mar 27, 2025 |
| FY2024 | Dec 31, 2022 | $47.67M | Mar 27, 2025 |
| FY2023 | Dec 31, 2021 | $100.32M | Mar 29, 2024 |
| FY2022 | Dec 31, 2020 | $25.38M | Mar 28, 2023 |
| FY2020 | Jun 30, 2020 | $5.00M | Sep 23, 2020 |
| FY2021 | Dec 31, 2019 | ($44.0K) | Mar 29, 2022 |
| FY2020 | Jun 30, 2019 | $23.6K | Sep 23, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($189.19M) | Mar 27, 2025 |
| FY2024 | Dec 31, 2023 | ($159.11M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($118.96M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($55.97M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | ($16.67M) | Mar 29, 2022 |
| FY2020 | Jun 30, 2020 | ($121.0K) | Sep 23, 2020 |
| FY2020 | Dec 31, 2019 | ($45.0K) | May 14, 2021 |
| FY2020 | Jun 30, 2019 | ($1.5K) | Sep 23, 2020 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $4.99M | Mar 27, 2025 |
| FY2024 | Dec 31, 2023 | $12.78M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $11.66M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $111.46M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $61.79M | Mar 29, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | (15) | Mar 27, 2025 |
| FY2024 | Dec 31, 2023 | (37) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | (3) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 28, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | (15) | Mar 27, 2025 |
| FY2024 | Sep 30, 2024 | (15) | Mar 27, 2025 |
| FY2024 | Dec 31, 2023 | (37) | Mar 27, 2025 |
| FY2024 | Sep 30, 2023 | (37) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | (3) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 28, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 2.24M | Mar 27, 2025 |
| FY2024 | Dec 31, 2023 | 1.07M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | 21.24M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | 21.06M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | 13.98M | Mar 29, 2022 |
| FY2020 | Jun 30, 2020 | 2.40M | Sep 23, 2020 |
| FY2020 | Dec 31, 2019 | 5.20M | May 14, 2021 |
| FY2020 | Jun 30, 2019 | 1.44M | Sep 23, 2020 |